Syon Capital’s Blueprint Medicines BPMC Stock Holding History

Syon Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,347	Closed	-$205K	–	596
2024 Q4	$205K	Buy	+2,347	New	+$215K	0.02%	515

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Syon Capital's BPMC Position: Q1 2025 in Review

Syon Capital sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 2,347 shares — an estimated $205K sold.

Syon Capital first reported a position in BPMC in Q4 2024 and held it in 1 quarter. The position peaked at $205K in Q4 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

Syon Capital reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
Syon Capital sold 2,347 Blueprint Medicines shares in Q1 2025, an estimated $205K.
Syon Capital first reported a position in Blueprint Medicines in Q4 2024 and held it in 1 quarter.
Syon Capital's Blueprint Medicines position peaked at $205K in Q4 2024.
352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Syon Capital's 13F filing for Q1 2025, filed 15 May 2025.